Mr. Speaker, with regard to (a), as of March 16, 2021, the quarterly breakdown of expected deliveries of approved vaccines from Pfizer-BioNTech and Moderna, AstraZeneca and Janssen) is eight million by the end of March, 28.5 million between April and the end of June, and 81.5 million between July and the end of September, for an aggregate total of 118 million by the end of September 2021. This includes accelerated doses of 1.5 million in March and one million in April and May. PSPC continues to work with vaccine suppliers to negotiate the early delivery of doses to Canadians, and as such, the information is subject to change.
In addition, information about the quantities of COVID-19 vaccines that have been delivered to provinces and territories to date is published by the Public Health Agency of Canada on the Vaccines and treatments for COVID-19: Vaccine rollout website at https://www.canada.ca/en/ public-health/services/diseases/ 2019-novel-coronavirus-infection/ prevention-risks/ covid-19-vaccine-treatment/ vaccine-rollout.html#a4. This information is updated weekly.
With regard to (b), information on Canada’s COVID-19 vaccine agreements, including a breakdown by supplier and number of doses, is published on Public Services and Procurement Canada’s Procuring vaccines for COVID-19 website at: https://www.canada.ca/en/ public-services-procurement/ services/procuring-vaccines- covid19.html.
To protect Canada’s negotiating position and to respect confidentiality clauses in our vaccine agreements, Public Services and Procurement Canada cannot unilaterally disclose details of specific agreements. We continue to seek opportunities to be as transparent as possible about our procurements in support of Canada’s COVID response, while respecting confidentiality agreements and protecting our negotiating position.